MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, IDYA had $28,657K increase in cash & cash equivalents over the period. -$73,466K in free cash flow.

Cash Flow Overview

Change in Cash
$28,657K
Free Cash flow
-$73,466K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Net loss
-113,698
Depreciation and amortization
2,700
Net amortization (accretion) of premiums (discounts) on marketable securities
9,976
Stock-based compensation
46,115
Amortization of right of use assets
1,893
Accounts receivable
0
Prepaid expenses and other assets
7,840
Accounts payable
2,697
Accrued and other liabilities
10,427
Contract assets and liabilities
5,973
Lease liabilities
2,557
Net cash used in operating activities
-71,098
Purchases of property and equipment, net
2,368
Purchases of marketable securities
607,889
Maturities of marketable securities
680,233
Net cash provided by (used in) investing activities
69,976
Proceeds from issuance of common stock in public offering, net of issuance costs
0
Proceeds from issuances of pre-funded warrants
0
Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs
24,855
Proceeds from exercise of common stock options
3,431
Proceeds from espp purchases
1,493
Net cash provided by financing activities
29,779
Net increase (decrease) in cash, cash equivalents and restricted cash
28,657
Cash and cash equivalents at beginning of period
85,183
Cash and cash equivalents at end of period
113,840
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences, Inc. (IDYA)